In adults with obesity and type 2 diabetes, fat mass lost during treatment with bimagrumab remains reduced for at least 12 weeks after stopping the drug.
See the scientific wording
Fat mass loss induced by bimagrumab in adults with obesity and type 2 diabetes is maintained for at least 12 weeks after the last dose.
Very strong evidence
Randomized trialsOne good-quality study supports this claim.
What the research says
1 study reviewedSupporting (1)
Randomized Controlled TrialHuman
The study showed that when people with obesity and type 2 diabetes took bimagrumab, they lost a lot of fat, and even after they stopped taking the drug, the fat didn’t come back for at least 12 weeks. This means the effect lasted beyond the treatment time.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
Bimagrumab binds to specific receptors on muscle and fat cells, blocking signals that normally limit muscle growth and promote fat storage. This allows muscle cells to build more protein and grow larger, while fat cells stop storing fat and break down existing fat. The new muscle mass stays increased and the fat loss persists even after the drug is stopped.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
In adults with obesity and type 2 diabetes, fat mass lost during treatment with bimagrumab remains reduced for at least 12 weeks after stopping the drug.
Mechanism
1 studyBimagrumab turns off signals that keep muscles small and fat cells full. This makes muscles grow bigger and fat cells shrink, and these changes stick around for weeks after stopping the drug because the new muscle stays and the fat doesn’t come back.
Bimagrumab binds to specific receptors on muscle and fat cells, blocking signals that normally limit muscle growth and promote fat storage. This allows muscle cells to build more protein and grow larger, while fat cells stop storing fat and break down existing fat. The new muscle mass stays increased and the fat loss persists even after the drug is stopped.
Bimagrumab binds with high affinity to ActRIIA and ActRIIB receptors on the surface of skeletal muscle and adipose tissue cells
Binding of bimagrumab prevents activin ligands from engaging ActRIIA/B and initiating downstream Smad2/3 phosphorylation
Inhibition of Smad2/3 signaling in muscle cells removes suppression of myogenesis and protein synthesis, leading to increased skeletal muscle mass
Inhibition of Smad2/3 signaling in adipocytes reduces adipogenesis and lipid storage, leading to decreased fat mass and reduced ectopic fat deposition in liver and muscle
Increased muscle mass and reduced fat mass persist for at least 12 weeks after cessation of bimagrumab due to stable remodeling of muscle and adipose tissue
Evidence from Studies
Supporting (1)
Community contributions welcome
370-OR: Optimized Weight Loss with Bimagrumab—Reduced Fat Mass with Increased Muscle Mass by Appetite-Independent Mechanisms
The study showed that when people with obesity and type 2 diabetes took bimagrumab, they lost a lot of fat, and even after they stopped taking the drug, the fat didn’t come back for at least 12 weeks. This means the effect lasted beyond the treatment time.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review of Bimagrumab Trials on Fat Mass Persistence Beyond Treatment in Obesity and Type 2 Diabetes
Population: Adults with obesity and type 2 diabetes; Intervention: Bimagrumab; Comparator: Placebo or other anti-obesity agents; Outcome: Change in fat mass at 12 weeks post-treatment; Duration: Minimum 12 weeks post-last dose across included trials.
Double-Blind, Placebo-Controlled Trial of Bimagrumab on Fat Mass Persistence at 12 Weeks Post-Treatment in Obesity and Type 2 Diabetes
Population: Adults with obesity and type 2 diabetes; Intervention: Bimagrumab administered for a defined period; Comparator: Placebo; Outcome: Fat mass measured by DEXA or MRI at 12 weeks after last dose; Duration: Treatment phase followed by 12-week post-treatment follow-up.
Prospective Cohort Study of Fat Mass Trajectory After Bimagrumab Cessation in Adults with Obesity and Type 2 Diabetes
Population: Adults with obesity and type 2 diabetes receiving bimagrumab; Intervention: Standard clinical use of bimagrumab; Comparator: None; Outcome: Fat mass measured at baseline, end of treatment, and 12 weeks post-treatment; Duration: Treatment plus 12-week post-treatment observation.
Case-Control Study Comparing Fat Mass Maintenance at 12 Weeks Post-Bimagrumab in Responders vs Non-Responders with Obesity and Type 2 Diabetes
Population: Adults with obesity and type 2 diabetes previously treated with bimagrumab; Cases: Those maintaining ≥5% fat mass loss at 12 weeks post-treatment; Controls: Those regaining fat mass to baseline; Outcome: Baseline demographic, metabolic, and treatment variables; Duration: Retrospective analysis of treatment and 12-week post-treatment data.
Case Report of Fat Mass Persistence at 12 Weeks After Bimagrumab Discontinuation in a Single Patient with Obesity and Type 2 Diabetes
Population: Single adult with obesity and type 2 diabetes; Intervention: Bimagrumab treatment; Outcome: Fat mass measured at end of treatment and 12 weeks post-treatment; Duration: Treatment period plus 12-week follow-up.